Sterling L Karakula1, Roger D Weiss2, Margaret L Griffin2, Allison M Borges3, Allen J Bailey4, R Kathryn McHugh2. 1. Division of Alcohol and Drug Abuse, McLean Hospital, 115 Mill Street, Belmont, MA 02478, United States. Electronic address: skarakula@harvard.mclean.edu. 2. Division of Alcohol and Drug Abuse, McLean Hospital, 115 Mill Street, Belmont, MA 02478, United States; Department of Psychiatry, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, United States. 3. Department of Psychology, Rutgers University, 152 Frelinghuysen Rd., Piscataway, NJ 08854, United States. 4. Division of Alcohol and Drug Abuse, McLean Hospital, 115 Mill Street, Belmont, MA 02478, United States.
Abstract
BACKGROUND: Among those with opioid use disorder, heroin use is associated with poorer prognosis relative to use of prescription opioids alone. However, relatively little is known about distinguishing features between those who use heroin relative to those who use prescription opioids. In the present study we evaluated differences in delay discounting in those with opioid use disorder based on primary opioid of use. Delay discounting is associated with a range of negative outcomes and is an important therapeutic target in this population. METHODS: Treatment-seeking adults with opioid dependence completed self-report measures including past-month opioid use and the Monetary Choice Questionnaire (Kirby and Marakovic, 1996; Kirby et al., 1999), a measure of delay discounting. Participants were divided into two groups based on whether they used any heroin in the past 30days or only prescription opioids, and delay discounting scores were compared between the groups. Group differences in sociodemographic or clinical variables were included in the analysis as covariates. RESULTS: Results from a forward stepwise linear regression indicated that heroin use was associated with significantly higher delay discounting (B=-0.99, SEB=0.34, t=-2.88, p=0.005), even when considering covariates. CONCLUSIONS: Adults with opioid dependence who exclusively used prescription opioids had lower delay discounting relative to those who used heroin. This finding contributes further to the literature suggesting that heroin use is associated with greater clinical severity among those with opioid use disorder. Copyright Â
BACKGROUND: Among those with opioid use disorder, heroin use is associated with poorer prognosis relative to use of prescription opioids alone. However, relatively little is known about distinguishing features between those who use heroin relative to those who use prescription opioids. In the present study we evaluated differences in delay discounting in those with opioid use disorder based on primary opioid of use. Delay discounting is associated with a range of negative outcomes and is an important therapeutic target in this population. METHODS: Treatment-seeking adults with opioid dependence completed self-report measures including past-month opioid use and the Monetary Choice Questionnaire (Kirby and Marakovic, 1996; Kirby et al., 1999), a measure of delay discounting. Participants were divided into two groups based on whether they used any heroin in the past 30days or only prescription opioids, and delay discounting scores were compared between the groups. Group differences in sociodemographic or clinical variables were included in the analysis as covariates. RESULTS: Results from a forward stepwise linear regression indicated that heroin use was associated with significantly higher delay discounting (B=-0.99, SEB=0.34, t=-2.88, p=0.005), even when considering covariates. CONCLUSIONS: Adults with opioid dependence who exclusively used prescription opioids had lower delay discounting relative to those who used heroin. This finding contributes further to the literature suggesting that heroin use is associated with greater clinical severity among those with opioid use disorder. Copyright Â
Authors: Leonard H Epstein; Jerry B Richards; Frances G Saad; Rocco A Paluch; James N Roemmich; Caryn Lerman Journal: Exp Clin Psychopharmacol Date: 2003-05 Impact factor: 3.157
Authors: Neal Doran; Patricia E Sanders; Nicole M Bekman; Matthew J Worley; Teresa K Monreal; Elizabeth McGee; Kevin Cummins; Sandra A Brown Journal: Nicotine Tob Res Date: 2011-03-24 Impact factor: 4.244
Authors: Andrew Rosenblum; Mark Parrino; Sidney H Schnoll; Chunki Fong; Carleen Maxwell; Charles M Cleland; Stephen Magura; J David Haddox Journal: Drug Alcohol Depend Date: 2007-03-26 Impact factor: 4.492
Authors: Janet Audrain-McGovern; Daniel Rodriguez; Leonard H Epstein; Jocelyn Cuevas; Kelli Rodgers; E Paul Wileyto Journal: Drug Alcohol Depend Date: 2009-05-14 Impact factor: 4.492
Authors: Brent A Moore; David A Fiellin; Declan T Barry; Lynn E Sullivan; Marek C Chawarski; Patrick G O'Connor; Richard S Schottenfeld Journal: J Gen Intern Med Date: 2007-04 Impact factor: 5.128
Authors: Christopher M Jones; Joseph Logan; R Matthew Gladden; Michele K Bohm Journal: MMWR Morb Mortal Wkly Rep Date: 2015-07-10 Impact factor: 17.586
Authors: Joshua L Gowin; Matthew E Sloan; Vijay A Ramchandani; Martin P Paulus; Scott D Lane Journal: Pharmacol Biochem Behav Date: 2017-09-18 Impact factor: 3.533
Authors: William Brady DeHart; Jonathan E Friedel; Meredith Berry; Charles C J Frye; Ann Galizio; Amy L Odum Journal: J Exp Anal Behav Date: 2020-08-27 Impact factor: 2.215